Broj 2.

  1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double blind, placebocontrolled trial. Neurol 1993;43:655-61.
  2. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in remitting and relapsing multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurol 1993;43:662-67.
  3. Polman CH, O`Connor PW, Havrdova E et al. A Randomised, Placebo/Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Eng J Med 2006;354(9):899-910.
  4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-23.
  5. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-801.
  6. Coles A, Brinar V, Arnold DL, et al. Efficasy and safety results from CARE-MS I: a phase 3 study comparing alemtuzumab and interferon-β-1a. Mult Scler J 2011: 17; S510.
  7. Muraro PA, Bielekova B. Emerging therapies for multiple sclerosis. Neurotherapeutics. 2007;4(4):676-92.
  8. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008;7(6):538-47.
  9. Wynn D et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010;9:381-90.
  10. Bielekova B, Becker B. Monoclonal antibodies in MS. Neurol 2010;74:1 Suppl 1:S31-S40.
  11. Hauser SL, Waubant E, Arnold DL, et al.; HERMES Trial Group. B-cell depletion with rituximab in relapsingremitting multiple sclerosis. N Engl J Med. 2008;358(7):676-88.
  12. Hawker K, O’Connor P, Freedman MS, et al.; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-contrlled multicenter trial. Ann Neurol. 2009;66(4):460-71.
  13. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-87.
  14. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the bête-interferons prescribed for MS. Neurol 2003; 61: 511-4.
  15. Clerico M, Barbero P, Contessa G et al. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007;259:104-8.
  16. Martini S, Peters H, Bohler T, Budde K. Current perspectives on FTY720. Expert Opin Investig Drugs. 2007;16(4):505-18.
  17. Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
  18. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362: 402-15.
  19. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-26.
  20. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGFbeta in Lewis rats. J Neuroimmunol. 2004;156(1-2):3-9.
  21. Polman C, Barkhof F, Sandberg-Wollheim M et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurol 2005; 64: 987-91.
  22. Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-92.
  23. Comi G, Jeffery D, Kappos L et al. Oral laquinimod slows disability progression and reduces severe relapses in the placebo-controlled phase III ALLEGRO trialfor the treatment of relapsing-remmiting multiple sclerosis. Mult Scler J 2011;17:S420-1.
  24. O’Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900
  25. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Collaborators (188). Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365(14): 1293-303.
  26. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebocontrolled phase IIb study. Lancet. 2008;372(9648):1463-72.
  27. Selmaj K, Gold R, Kappos L, Bar-Or A et al. Safety and tolerability of BG-12 in the phase 3 DEFINE trial in patients with relapsing-remitting multiple sclerosis. Mult Scler J 2011;17:S451

Pages: 1 2 3 4 5 6 7 8 9 10


O časopisu Neurovesti

„Neurovesti“ predstavljaju elektronsku publikaciju Društva mladih neurologa Srbije sa besplatnim pristupom preko web-adrese www.neurovesti.org, i dinamikom objavljivanja na mesečnom nivou.

Opširnije

Kalendar dešavanja
<< Dec 2021. >>
MTWTFSS
29 30 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 1 2
NOVO – Škola epilepsija – “Lečenje epilepsije vođeno etiologijom”
pratite-dns